Background: The purpose of this study was to evaluate the discriminatory capability of the Khorana, PROTECHT, CONKO, and COMPASS-CAT scores in ambulatory patients with lung cancer. Methods: This retrospective cohort study included 591 patients with newly diagnosed lung cancer. A symptomatic or incidental VTE occurred in 108 patients. Results: The Khorana score at a 2-point threshold had a discriminatory capability with an odds ratio (OR) of 1.80 and an AUC of 0.57 for 6 months, and an OR of 1.51 and an AUC of 0.55 for 12 months. The CONKO score at a 2-point threshold had a stronger discriminatory capability for both 6 months and 12 months with ORs of 3.00 and 2.13, and AUCs of 0.63 and 0.59, respectively. Additionally, higher white blood cell counts, higher neutrophil counts, hypoalbuminaemia, and not undergoing lung surgery were related to VTE occurrence (p< 0.05). Conclusions: The Khorana score with the 2-point threshold was validated in ambulatory patients with lung cancer, with the results indicating a decline in its discriminatory capability over time (at 12 months vs. 6 months from diagnosis). The CONKO score at the original 2-point threshold showed a stronger discriminatory capability but further validation with a larger sample size is recommended. The identified predictors should be further investigated in future research.
背景：本研究旨在评估Khorana、PROTECHT、CONKO及COMPASS-CAT评分在门诊肺癌患者中的鉴别能力。方法：本回顾性队列研究纳入591例新诊断肺癌患者，其中108例发生症状性或偶发性静脉血栓栓塞（VTE）。结果：以2分为界值的Khorana评分在6个月随访期内的鉴别能力比值比（OR）为1.80，受试者工作特征曲线下面积（AUC）为0.57；在12个月随访期内OR为1.51，AUC为0.55。而以2分为界值的CONKO评分在6个月和12个月随访期内均表现出更强的鉴别能力，OR值分别为3.00和2.13，AUC分别为0.63和0.59。此外，较高的白细胞计数、中性粒细胞计数、低白蛋白血症以及未接受肺部手术与VTE发生相关（p<0.05）。结论：以2分为界值的Khorana评分在门诊肺癌患者中得到验证，但其鉴别能力随时间推移呈下降趋势（诊断后12个月较6个月）。原始2分界值的CONKO评分显示出更强的鉴别能力，但建议通过更大样本量进一步验证。已识别的预测因素应在未来研究中深入探讨。
肿瘤(癌症)患者之家